We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
Ecolab benefits from strong high-tech demand, digital growth and a robust innovation pipeline.
Digital sales rise 27% in Q2, while organic sales increase 5% on higher pricing and volume growth.
Ecolab uses energy surcharges, productivity and cost savings to help offset rising input costs.
Ecolab Inc. (ECL - Free Report) has been gaining from its solid product portfolio. The optimism, led by a solid second-quarter 2026 performance and continued focus on research and development, is expected to contribute further. However, concerns regarding cost fluctuations persist.
This Zacks Rank #3 (Hold) stock has gained 2.5% in the year-to-date period compared with the industry’s 6.3% growth. The S&P 500 Composite has increased 11% during the same time frame.
The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $77.9 billion. It projects 12.6% growth for the next five years and expects to maintain a strong performance in the future. Ecolab’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters, and met once, delivering an average surprise of 0.49%.
Image Source: Zacks Investment Research
Reasons Favoring Ecolab’s Growth
Ecolab’s Global High-Tech Business & Digital Platform: Per management, Ecolab’s Global High-Tech business remains a key long-term growth driver, supported by rising semiconductor manufacturing and data-center infrastructure investments worldwide. In first-quarter 2026, the segment delivered more than 20% organic sales growth, driven by new business wins across microelectronics and data centers. Management also noted that the Ovivo Electronics acquisition strengthens Ecolab’s ultrapure water capabilities for semiconductor fabs and, together with the pending CoolIT Systems acquisition, is expected to create a roughly $1.5 billion Global High-Tech platform.
Meanwhile, Ecolab Digital continues to scale as another important growth engine, with annualized revenues surpassing $400 million. Management highlighted that the platform leverages AI, predictive analytics, remote monitoring and automation to enhance customer productivity and sustainability outcomes, while addressing a $13 billion market opportunity, including nearly $3 billion within the existing customer base.
Strong Product Portfolio With a Focus on R&D: In first-quarter 2026, Ecolab’s organic sales rose 4%, driven by 3% pricing and 1% volume growth, reflecting the strong value proposition of its portfolio. Per management, the company continues to benefit from a robust innovation pipeline, with increasing focus on digitally enabled solutions that enhance customer productivity and sustainability.
Platforms like 3D TRASAR and other connected monitoring solutions are gaining traction by helping customers optimize water usage, energy consumption and operational efficiency. Management noted that these technology-driven offerings deliver measurable savings, strengthen long-term customer relationships and support premium pricing, reinforcing Ecolab’s competitive position across its end markets.
Strong Q2 Results: ECL exited the second quarter of 2026 with better-than-expected earnings and revenues. The company registered a robust year-over-year uptick in its top and bottom lines, along with solid performances across all segments. The expansion of the organic operating margin bodes well for the stock.
In the second quarter of 2026, Ecolab’s Digital sales increased 27% year over year to $121 million, driven by strong growth across software and enabling hardware subscriptions.
Organic sales were $4.28 billion, up 5% from $4.09 billion in the year-ago quarter. Reported volume increased 1% despite a nearly 1% headwind from customer operations disrupted by the Middle East conflict. Pricing improved to 4%, reflecting the initial benefits of the company’s energy surcharge implementation.
A Factor That May Offset ECL’s Gains
Cost Fluctuations: Ecolab remains exposed to swings in raw material, manufacturing and logistics costs. During the second quarter of 2026, the Middle East conflict contributed to energy-market volatility, supply-chain disruption and higher input costs across the company’s global network. Ecolab began implementing an energy surcharge during the quarter, helping to lift pricing by 4%, and management expects pricing to reach 5%-6% in the second half. The current plan assumes pricing, volume growth, productivity and other cost savings will offset these cost increases.
Estimate Trend
Ecolab is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has remained stable at $8.19 per share.
The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is pegged at $4.68 billion, indicating a 12.3% improvement from the year-ago quarter’s reported number.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
Key Takeaways
Ecolab Inc. (ECL - Free Report) has been gaining from its solid product portfolio. The optimism, led by a solid second-quarter 2026 performance and continued focus on research and development, is expected to contribute further. However, concerns regarding cost fluctuations persist.
This Zacks Rank #3 (Hold) stock has gained 2.5% in the year-to-date period compared with the industry’s 6.3% growth. The S&P 500 Composite has increased 11% during the same time frame.
The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $77.9 billion. It projects 12.6% growth for the next five years and expects to maintain a strong performance in the future. Ecolab’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters, and met once, delivering an average surprise of 0.49%.
Image Source: Zacks Investment Research
Reasons Favoring Ecolab’s Growth
Ecolab’s Global High-Tech Business & Digital Platform: Per management, Ecolab’s Global High-Tech business remains a key long-term growth driver, supported by rising semiconductor manufacturing and data-center infrastructure investments worldwide. In first-quarter 2026, the segment delivered more than 20% organic sales growth, driven by new business wins across microelectronics and data centers. Management also noted that the Ovivo Electronics acquisition strengthens Ecolab’s ultrapure water capabilities for semiconductor fabs and, together with the pending CoolIT Systems acquisition, is expected to create a roughly $1.5 billion Global High-Tech platform.
Meanwhile, Ecolab Digital continues to scale as another important growth engine, with annualized revenues surpassing $400 million. Management highlighted that the platform leverages AI, predictive analytics, remote monitoring and automation to enhance customer productivity and sustainability outcomes, while addressing a $13 billion market opportunity, including nearly $3 billion within the existing customer base.
Strong Product Portfolio With a Focus on R&D: In first-quarter 2026, Ecolab’s organic sales rose 4%, driven by 3% pricing and 1% volume growth, reflecting the strong value proposition of its portfolio. Per management, the company continues to benefit from a robust innovation pipeline, with increasing focus on digitally enabled solutions that enhance customer productivity and sustainability.
Platforms like 3D TRASAR and other connected monitoring solutions are gaining traction by helping customers optimize water usage, energy consumption and operational efficiency. Management noted that these technology-driven offerings deliver measurable savings, strengthen long-term customer relationships and support premium pricing, reinforcing Ecolab’s competitive position across its end markets.
Strong Q2 Results: ECL exited the second quarter of 2026 with better-than-expected earnings and revenues. The company registered a robust year-over-year uptick in its top and bottom lines, along with solid performances across all segments. The expansion of the organic operating margin bodes well for the stock.
In the second quarter of 2026, Ecolab’s Digital sales increased 27% year over year to $121 million, driven by strong growth across software and enabling hardware subscriptions.
Organic sales were $4.28 billion, up 5% from $4.09 billion in the year-ago quarter. Reported volume increased 1% despite a nearly 1% headwind from customer operations disrupted by the Middle East conflict. Pricing improved to 4%, reflecting the initial benefits of the company’s energy surcharge implementation.
A Factor That May Offset ECL’s Gains
Cost Fluctuations: Ecolab remains exposed to swings in raw material, manufacturing and logistics costs. During the second quarter of 2026, the Middle East conflict contributed to energy-market volatility, supply-chain disruption and higher input costs across the company’s global network. Ecolab began implementing an energy surcharge during the quarter, helping to lift pricing by 4%, and management expects pricing to reach 5%-6% in the second half. The current plan assumes pricing, volume growth, productivity and other cost savings will offset these cost increases.
Estimate Trend
Ecolab is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has remained stable at $8.19 per share.
The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is pegged at $4.68 billion, indicating a 12.3% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.